Publication:
Human single-chain antibodies that neutralize elastolytic activity of pseudomonas aeruginosa lasb

dc.contributor.authorSirijan Santajiten_US
dc.contributor.authorThida Kong-Ngoenen_US
dc.contributor.authorManas Chongsa-Nguanen_US
dc.contributor.authorUsa Boonyuenen_US
dc.contributor.authorPornpan Pumiraten_US
dc.contributor.authorNitat Sookrungen_US
dc.contributor.authorWanpen Chaicumpaen_US
dc.contributor.authorNitaya Indrawattanaen_US
dc.contributor.otherSiriraj Hospitalen_US
dc.contributor.otherFaculty of Tropical Medicine, Mahidol Universityen_US
dc.contributor.otherWalailak Universityen_US
dc.contributor.otherPathumthani Universityen_US
dc.date.accessioned2022-08-04T08:08:33Z
dc.date.available2022-08-04T08:08:33Z
dc.date.issued2021-06-01en_US
dc.description.abstractLasB (elastase/pseudolysin) is an injurious zinc-metalloprotease secreted by the infecting Pseudomonas aeruginosa. LasB is recognized as the bacterial key virulence factor for establishment of successful infection, acquisition of nutrients, dissemination, tissue invasion, and immune modulation and evasion. LasB digests a variety of the host tissue proteins, extracellular matrices, as well as components of both innate and adaptive immune systems, including immunoglobulins, complement proteins, and cytokines. Thus, this enzyme is an attractive target for disarming the P. aeruginosa. This study generated human single-chain antibodies (HuscFvs) that can neutralize the elastolytic activity of native LasB by using phage display technology. Gene sequences coding HuscFvs (huscfvs) isolated from HuscFv-displaying phage clones that bound to enzymatically active LasB were sub-cloned to expression plasmids for large scale production of the recombinant HuscFvs by the huscfv-plasmid transformed Escherichia coli. HuscFvs of two transformed E. coli clones, i.e., HuscFv-N42 and HuscFv-N45, neutralized the LasB elastolytic activities in vitro. Computer simulation by homology modeling and molecular docking demonstrated that antibodies presumptively formed contact interfaces with the LasB residues critical for the catalytic activity. Although the LasB neutralizing mechanisms await elucidation by laboratory experiments, the HuscFvs should be tested further towards the clinical application as a novel adjunctive therapeutics to mitigate severity of the diseases caused by P. aeruginosa.en_US
dc.identifier.citationPathogens. Vol.10, No.6 (2021)en_US
dc.identifier.doi10.3390/pathogens10060765en_US
dc.identifier.issn20760817en_US
dc.identifier.other2-s2.0-85108988238en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/76148
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85108988238&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleHuman single-chain antibodies that neutralize elastolytic activity of pseudomonas aeruginosa lasben_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85108988238&origin=inwarden_US

Files

Collections